Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11974254 | 0.83 | NPSR1 (0.41) | PYCR1CNR2IDO1L3MBTL1ALDH1A1 | |
| SCHEMBL10330355 | 0.83 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CL3MBTL1PSMD14 | |
| SCHEMBL23516584 | 0.80 | KMT2A (0.39) | TYRPYCR1IDO1ALDH1A1TDP1 | |
| SCHEMBL10080950 | 0.79 | ALDH1A1 (0.60) | CNR2CNR1L3MBTL1PSMD14ALDH1A1 | |
| SCHEMBL13069328 | 0.78 | SLC2A1 (0.55) | ADRA2AADRA2BADRA2CL3MBTL1ALDH1A1 | |
| SCHEMBL12648604 | 0.78 | HPGD (0.42) | PYCR1IDO1L3MBTL1 | |
| SCHEMBL18805967 | 0.78 | TYR (0.44) | TYRPYCR1CNR2CNR1IDO1 | |
| SCHEMBL12922764 | 0.78 | TYR (0.44) | TYRPYCR1CNR2CNR1IDO1 | |
| SCHEMBL12374444 | 0.77 | GRK6 (0.49) | ADRA2AADRA2BADRA2CCNR2L3MBTL1 | |
| SCHEMBL6782387 | 0.77 | L3MBTL1 (0.55) | TYRPYCR1L3MBTL1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| EP-3515912-B1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NAT RECH SCIENT (FR) | 2020-10-14 | — | — | EP | disclosed |
| US-20180210240-A1 | OPTICAL FILTER WITH LIGHT SOURCE | SWITCH MATERIALS, INC. (CA) | 2018-07-26 | — | — | US | disclosed |
| US-9910301-B2 | Switchable optical filter apparatus with light | SWITCH MATERIALS, INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20170362221-A1 | INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-21 | — | — | US | disclosed |
| US-20160083398-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | SWITCH MATERIALS, INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-9227986-B2 | Diarylethene compounds and uses thereof | SWITCH MATERIALS, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-20150036204-A1 | OPTICAL FILTER WITH LIGHT SOURCE | SWITCH MATERIALS, INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-20140256936-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | SWITCH MATERIALS, INC. (CA) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | ADRA2A 3473/4885ADRA2B 3211/4885ADRA2C 3104/4885 |
| US-20140256936-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | KCNH2, KCNH3, SCN2B | ADRA2A 656/4885ADRA2B 294/4885ADRA2C 883/4885 |
| US-20160083398-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | KCNH2, KCNH3, SCN2B | ADRA2A 656/4885ADRA2B 294/4885ADRA2C 883/4885 |
| US-20170362221-A1 | INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1 | GLS, GLS2, GLUL | ADRA2A 4715/4885ADRA2B 4552/4885ADRA2C 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.